InVivo Therapeutics Holdings Corp. (NVIV) Shares Bought by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. increased its holdings in InVivo Therapeutics Holdings Corp. (OTCMKTS:NVIV) by 144.5% in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 167,318 shares of the biotechnology company’s stock after buying an additional 98,879 shares during the quarter. Goldman Sachs Group Inc. owned about 0.52% of InVivo Therapeutics Holdings Corp. worth $452,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the business. Legal & General Group Plc boosted its position in InVivo Therapeutics Holdings Corp. by 4,427.9% in the second quarter. Legal & General Group Plc now owns 503,407 shares of the biotechnology company’s stock worth $1,359,000 after purchasing an additional 492,289 shares during the last quarter. Blair William & Co. IL purchased a new position in InVivo Therapeutics Holdings Corp. in the second quarter worth about $159,000. Finally, LMR Partners LLP purchased a new position in InVivo Therapeutics Holdings Corp. in the second quarter worth about $159,000.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.chaffeybreeze.com/2017/11/14/invivo-therapeutics-holdings-corp-nviv-shares-bought-by-goldman-sachs-group-inc.html.

Shares of InVivo Therapeutics Holdings Corp. (OTCMKTS:NVIV) opened at $1.27 on Tuesday. InVivo Therapeutics Holdings Corp. has a 12 month low of $1.10 and a 12 month high of $5.90.

InVivo Therapeutics Holdings Corp. (OTCMKTS:NVIV) last released its quarterly earnings data on Monday, October 30th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.06).

NVIV has been the topic of a number of analyst reports. Raymond James Financial, Inc. cut InVivo Therapeutics Holdings Corp. from an “outperform” rating to a “market perform” rating in a research report on Monday, July 31st. ValuEngine cut InVivo Therapeutics Holdings Corp. from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st.

InVivo Therapeutics Holdings Corp. Profile

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc, is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury.

Want to see what other hedge funds are holding NVIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for InVivo Therapeutics Holdings Corp. (OTCMKTS:NVIV).

Institutional Ownership by Quarter for InVivo Therapeutics Holdings Corp. (OTCMKTS:NVIV)

Receive News & Ratings for InVivo Therapeutics Holdings Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVivo Therapeutics Holdings Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply